This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Park, J. M. Articles by Lin, H. J. Search for Related Content PubMed PubMed Citation Articles by Park, J. M. Articles by Lin, H. J.

Hematopoietic Prostaglandin D Synthase Suppresses Intestinal Adenomas in Apc^Min/+ Mice

¹ Division of Medical Genetics, Department of Pediatrics and ² Department of Pathology, Los Angeles Biomedical Research Institute, Harbor-University of California-Los Angeles Medical Center, Torrance, California; ³ Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts; ⁴ Department of Molecular Behavioral Biology, Osaka Bioscience Institute, Osaka, Japan; and ⁵ Unidad de Investigacion, Hospital Universitario Canarias, Laguna, Tenerife, Spain

Requests for reprints: Henry J. Lin, Division of Medical Genetics, Harbor-University of California-Los Angeles Medical Center, 1124 West Carson Street, Torrance, CA 90502. Phone: 310-222-3783; Fax: 310-328-9921; E-mail: hlin{at}labiomed.org.

Aspirin and other nonsteroidal anti-inflammatory drugs prevent some cases of colon cancer by inhibiting prostaglandin (PG) synthesis. PGE₂ promotes colon neoplasia, as shown by knockout mouse studies on enzymes and receptors in the PG cascade. A few experiments 20 to 30 years ago suggested that PGD₂ may suppress tumors, but a role for biosynthetic enzymes for PGD₂ in tumor development has not been studied. We report here that disruption of the gene for hematopoietic PGD synthase in Apc^Min/+ mice led to 50% more intestinal adenomas compared with controls. Tumor size was not affected. By immunohistochemistry, we detected hematopoietic PGD synthase mainly in macrophages and monocytes of the gut mucosa. The mean number of tumors did not increase with knockout of the gene for the lipocalin type of the enzyme, which is not produced in the intestine. On the other hand, Apc^Min/+ mice with transgenic human hematopoietic PGD synthase tended to have 80% fewer intestinal adenomas. The transgene produced high mRNA levels (375-fold over endogenous). There was a suggestion of higher urinary excretion of 11ß-PGF₂ and a lower excretion of a PGE₂ metabolite in transgenic mice, but differences (30–40%) were not statistically significant. The results support an interpretation that hematopoietic PGD synthase controls an inhibitory effect on intestinal tumors. Further studies will be needed to prove possible mechanisms, such as routing of PG production away from protumorigenic PGE₂ or inhibition of the nuclear factor-B cascade by PGD₂ metabolites. [Cancer Res 2007;67(3):881–9]

This article has been cited by other articles:

				A. E. Moore, A. Greenhough, H. R. Roberts, D. J. Hicks, H. A. Patsos, A. C. Williams, and C. Paraskeva HGF/Met signalling promotes PGE2 biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells Carcinogenesis, October 1, 2009; 30(10): 1796 - 1804. [Abstract] [Full Text] [PDF]